Australia's largest stock trading and investment forum Australia's #1 stock forum

CYP

Click for more information

3.57%

29.0¢ cynata therapeutics limited

Ann: Strategic Review of Cynata Clinical Development Portfolio, page-14

First 14 Last

Share
Profile

Follow
Bazsa

3,865 Posts.

1308

25/07/23

14:31

Post #: 68970379
Share

Originally posted by col69: ↑

1. New CEO seems to be following the old CEO - can't help but mention Mesoblast in interviews; and

2. Openly admits that if Mesoblast receives FDA approval that there is the possibility of off label use in adults - how anyone can believe that this won't impact recruitment in some way for the proposed CYP phase 2 GVHD trial is beyond me ? Off label use could include aGVHD as well as sr-GVHD if medical professionals want to try it ? Prospective CYP trial participants then have to make a choice of do I choose being guaranteed a similar treatment off label or a 50% chance of placebo (SOC) in the CYP trial ? Will be interesting to watch recruitment numbers once it all gets underway IMO ?

Maybe Dr Kelly is attempting to soften the blow in case further down the track even after (IF) the CYP GVHD trial starts he can justify pulling it due to lack of recruitment numbers ?

I bought some in the 14's for the OA trial alone .... GLTAH

Expand

You are more game than I.
The old had problems, the new still has the same problems. They just dont go away.
CYP is only getting in line if MSB fail to get approval.

The trial that CYP has put forward is a very good indication that they know they would not be able to match effecacy to MSB .

CYP Price at posting: 15.0¢ Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

NXM

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

SFX

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

NIM

Nimy extends sulphide targets at Mons with new anomalies identified

There are more pages in this discussion • 3 more messages in this thread...

First 14 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 29.0¢		Change 0.010(3.57%)		Mkt cap ! $52.09M

Open	High	Low	Value	Volume
27.0¢	29.0¢	27.0¢	$8.285K	29.43K

Buyers (Bids)

No.	Vol.	Price($)
1	35573	28.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.0¢	16184	1

View Market Depth

No.	Vol.	Price($)
1	35573	0.280
1	1492	0.270
2	127000	0.260
1	8000	0.245
3	125942	0.240

Price($)	Vol.	No.
0.290	16184	1
0.295	10160	1
0.300	30000	1
0.310	13257	2
0.325	15000	1

Last trade - 15.57pm 27/06/2024 (20 minute delay)

CYP (ASX) Chart